IND Swift Limited — Terbinafine Exporter Profile
Indian Pharmaceutical Exporter · #6 for Terbinafine · $1.4M export value · DGFT Verified
IND Swift Limited is the #6 Indian exporter of Terbinafine with $1.4M in export value and 40 verified shipments. IND Swift Limited holds a 4.2% market share in Terbinafine exports across 7 countries. The company exports 13 pharmaceutical products worth $36.7M across 9 therapeutic categories.
IND Swift Limited — Terbinafine Export Profile: Buyers & Destinations
Where Does IND Swift Limited Export Terbinafine?
| Country | Value | Shipments | Share |
|---|---|---|---|
| NETHERLANDS | $329.0K | 16 | 45.5% |
| FRANCE | $284.2K | 11 | 39.3% |
| BELGIUM | $70.2K | 8 | 9.7% |
| IRELAND | $22.1K | 2 | 3.1% |
| ITALY | $11.2K | 1 | 1.6% |
| NEPAL | $6.0K | 1 | 0.8% |
| HUNGARY | $108 | 1 | 0.0% |
IND Swift Limited exports Terbinafine to 7 countries. The largest destination is NETHERLANDS accounting for 45.5% of IND Swift Limited's Terbinafine shipments, followed by FRANCE (39.3%) and BELGIUM (9.7%). These destinations reflect IND Swift Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Terbinafine from IND Swift Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $121.5K | 5 |
| CSP VIATRIS SANTE AT CSP-LAB | NETHERLANDS | $120.9K | 3 |
| MYLAN IRELAND LTD | NETHERLANDS | $104.3K | 6 |
| VIATRIS BV C/O LIVLINA | BELGIUM | $59.1K | 7 |
| CSP VIATRIS SANTE AT CSP-LAB 76-78 | FRANCE | $52.5K | 2 |
| M/S. CSP MYLAN SAS AT CSP LABO 274 | FRANCE | $50.0K | 1 |
| CSP VIATRIS SANTE AT CSP LABO 76 78 | FRANCE | $50.0K | 1 |
| MYLAN IRELAND LIMITED | NETHERLANDS | $40.2K | 1 |
| M/S. MYLAN ITALIA S.R.L., | NETHERLANDS | $18.4K | 2 |
| UNITED DRUG DISTRIBUTION | NETHERLANDS | $15.1K | 1 |
IND Swift Limited supplies Terbinafine to 21 buyers globally. The largest buyer is CSP MYLAN SAS AT CSP LABO 274 (FRANCE), followed by CSP VIATRIS SANTE AT CSP-LAB (NETHERLANDS) and MYLAN IRELAND LTD (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Terbinafine Export Value and How Much Does IND Swift Limited Contribute?
India exported $22.3M worth of Terbinafine through 3,118 shipments from 292 suppliers to 121 countries, serving 589 buyers globally. IND Swift Limited contributes $1.4M to this total, accounting for 4.2% of India's Terbinafine exports. IND Swift Limited ships Terbinafine to 7 countries through 21 buyers.
What Is the Average Shipment Value for IND Swift Limited's Terbinafine Exports?
IND Swift Limited's average Terbinafine shipment value is $34.0K per consignment, based on 40 shipments totaling $1.4M. The largest destination is NETHERLANDS (45.5% of IND Swift Limited's Terbinafine exports).
How Does IND Swift Limited Compare to Other Indian Terbinafine Exporters?
IND Swift Limited ranks #6 among 292 Indian Terbinafine exporters with a 4.2% market share. The top 3 exporters are AUROBINDO PHARMA LTD ($10.2M), AUROBINDO PHARMA LIMITED ($2.4M), MANKIND PHARMA LIMITED ($2.0M). IND Swift Limited processed 40 shipments to 7 destination countries.
What Terbinafine Formulations Does IND Swift Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TERBINAFINA VIATRIS 250 MG (TERBINAFINE250MG TABLETS) BATCH NO.AHS10624,0724,0824,0924,1024,1124 MFG MAR-24 EXP MAR-27 | $120.9K | 3 |
| TERBINAFINE MYLAN 250 MG TABLETS (TERBIN | $51.8K | 5 |
| TERBINAFINE MYLAN 250MG TABLETS TERBINAF | $51.0K | 2 |
| TERBINAFINE MYLAN 250 MG TABLETS PACK 2 | $50.0K | 1 |
| TERBINAFINE VITARIS 250MG (TERBINAFINE | $50.0K | 1 |
| TERBINAFINE VIATRIS 250MG TERBINAFINE 250MG TABLETS 814380X2X14T BT NO AHS10225MFG APR 25 EXP APR 28 | $50.0K | 1 |
| TERBINAFINE VIATRIS 250 MG TABLETS BT NOAHS11224/1324/1424A MFG-APR 2024 EXP-APR 2027 (26112 X 2 X14T | $46.3K | 1 |
| TERBINAFINE MYLAN 250 MG TABLETS TERBINA | $45.0K | 2 |
| TERBINAFINE MYLAN 250 MG COMPRIMIDOS (TE | $40.2K | 1 |
| TERBINAFINE VIATRIS 250 MG(TERBINAFINE 250MG TABLETS)(3297X7X14T)BT NO AJI10225MFG DT MAR-2025 EXP DT FEB-2028 | $20.9K | 1 |
IND Swift Limited exports 32 distinct Terbinafine formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TERBINAFINA VIATRIS 250 MG (TERBINAFINE250MG TABLETS) BATCH with 3 shipments worth $120.9K.
How Does IND Swift Limited Compare to Nearest Terbinafine Exporters?
Exporters ranked immediately above and below #6 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 4 | MANKIND PHARMA LIMITED | $2.0M | 111 | 10 | $17.8K |
| 5 | CIPLA LIMITED | $1.3M | 52 | 7 | $25.8K |
| 6 | IND SWIFT LIMITED ★ | $1.2M | 40 | 7 | $28.8K |
| 7 | ORBION PHARMACEUTICALS PRIVATE LIMITED | $1.1M | 46 | 1 | $24.5K |
| 8 | MEDREICH LIMITED | $865.1K | 31 | 2 | $27.9K |
IND Swift Limited ranks #6 among 292 Indian Terbinafine exporters. Average shipment value of $28.8K compared to the market average of $76.4K. The closest competitors by value are MANKIND PHARMA LIMITED and CIPLA LIMITED.
Which Indian Ports Ship Terbinafine Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 437 | 14.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 396 | 12.7% |
| DELHI AIR CARGO ACC (INDEL4) | 354 | 11.4% |
| DELHI AIR | 275 | 8.8% |
| NHAVA SHEVA SEA (INNSA1) | 233 | 7.5% |
| HYDERABAD ICD (INSNF6) | 111 | 3.6% |
| JNPT/ NHAVA SHEVA SEA | 106 | 3.4% |
| Bombay Air | 89 | 2.9% |
Geopolitical & Trade Policy Impact on IND Swift Limited's Terbinafine Exports
Ind-Swift Laboratories' export operations have been influenced by recent geopolitical developments. The Israel-Iran conflict has heightened security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and increased freight rates by 40–50% on key India–Europe routes, impacting the company's logistics and cost structures. (livemint.com)
Conversely, the India–European Union Free Trade Agreement (India–EU FTA), concluded in January 2026, is poised to benefit Indian pharmaceutical exporters. The agreement eliminates tariffs on most European pharmaceutical imports, enhancing the competitiveness of Indian products in the EU market. This development presents an opportunity for Ind-Swift Laboratories to expand its footprint in Europe. (en.wikipedia.org)
In the United States, the reshoring of pharmaceutical manufacturing and potential imposition of tariffs on imports pose challenges for Indian exporters. While there are currently no import duties on Indian pharmaceutical products entering the US, the introduction of tariffs could affect the profitability of low-margin generic drugs, potentially leading to market exits. (cfo.economictimes.indiatimes.com)
IND Swift Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains paramount for Indian pharmaceutical exporters. Ind-Swift Laboratories has demonstrated a commitment to quality by adhering to Good Manufacturing Practices (GMP) as stipulated by the US FDA, WHO, and EU authorities. The company's manufacturing facilities in Punjab and Jammu have been inspected and approved by these regulatory bodies, facilitating access to regulated markets.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous investment in quality systems and supply chain transparency. Ind-Swift Laboratories' focus on high-margin formulations underscores the importance of maintaining stringent quality standards to meet global regulatory requirements and sustain market access.
About IND Swift Limited
IND Swift Limited exports 13 products worth $36.7M. Beyond Terbinafine, top products include Fexofenadine, Ramipril, Clarithromycin, Loratadine, Ezetimibe. View the complete IND Swift Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Terbinafine — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Terbinafine shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: IND Swift Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 40 individual customs records matching IND Swift Limited exporting Terbinafine, covering 32 formulations to 7 countries via 21 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 121+ countries, 589+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Terbinafine Export Data from IND Swift Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for IND Swift Limited's Terbinafine exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
IND Swift Limited
Full Company Profile →
13 products · $36.7M total trade · 9 categories
Terbinafine Stats
Company Overview
Top Products by IND Swift Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for IND Swift Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Terbinafine. For current shipment-level data, contact TransData Nexus.